1
|
Ouyang X, Telli ML, Wu JC. Induced Pluripotent Stem Cell-Based Cancer Vaccines. Front Immunol 2019; 10:1510. [PMID: 31338094 PMCID: PMC6628907 DOI: 10.3389/fimmu.2019.01510] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Accepted: 06/17/2019] [Indexed: 12/12/2022] Open
Abstract
Over a century ago, it was reported that immunization with embryonic/fetal tissue could lead to the rejection of transplanted tumors in animals. Subsequent studies demonstrated that vaccination of embryonic materials in animals induced cellular and humoral immunity against transplantable tumors and carcinogen-induced tumors. Therefore, it has been hypothesized that the shared antigens between tumors and embryonic/fetal tissues (oncofetal antigens) are the key to anti-tumor immune responses in these studies. However, early oncofetal antigen-based cancer vaccines usually utilize xenogeneic or allogeneic embryonic stem cells or tissues, making it difficult to tease apart the anti-tumor immunity elicited by the oncofetal antigens vs. graft-vs.-host responses. Recently, one oncofetal antigen-based cancer vaccine using autologous induced pluripotent stem cells (iPSCs) demonstrated marked prophylactic and therapeutic potential, suggesting critical roles of oncofetal antigens in inducing anti-tumor immunity. In this review, we present an overview of recent studies in the field of oncofetal antigen-based cancer vaccines, including single peptide-based cancer vaccines, embryonic stem cell (ESC)- and iPSC-based whole-cell vaccines, and provide insights on future directions.
Collapse
Affiliation(s)
- Xiaoming Ouyang
- Cardiovascular Institute, School of Medicine, Stanford University, Stanford, CA, United States.,Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University, Stanford, CA, United States
| | - Melinda L Telli
- Department of Medicine, Stanford University, Stanford, CA, United States
| | - Joseph C Wu
- Cardiovascular Institute, School of Medicine, Stanford University, Stanford, CA, United States.,Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University, Stanford, CA, United States.,Department of Medicine, Stanford University, Stanford, CA, United States.,Department of Radiology, Stanford University, Stanford, CA, United States
| |
Collapse
|
2
|
Tabatabaei M, Mosaffa N, Ghods R, Nikoo S, Kazemnejad S, Khanmohammadi M, Mirzadegan E, Mahmoudi AR, Bolouri MR, Falak R, Keshavarzi B, Ramezani M, Zarnani AH. Vaccination with human amniotic epithelial cells confer effective protection in a murine model of Colon adenocarcinoma. Int J Cancer 2017; 142:1453-1466. [PMID: 29139122 DOI: 10.1002/ijc.31159] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 09/21/2017] [Accepted: 10/19/2017] [Indexed: 12/16/2022]
Abstract
As a prophylactic cancer vaccine, human amniotic membrane epithelial cells (hAECs) conferred effective protection in a murine model of colon cancer. The immunized mice mounted strong cross-protective CTL and antibody responses. Tumor burden was significantly reduced in tumor-bearing mice after immunization with hAECs. Placental cancer immunotherapy could be a promising approach for primary prevention of cancer. In spite of being the star of therapeutic strategies for cancer treatment, the results of immunotherapeutic approaches are still far from expectations. In this regard, primary prevention of cancer using prophylactic cancer vaccines has gained considerable attention. The immunologic similarities between cancer development and placentation have helped researchers to unravel molecular mechanisms responsible for carcinogenesis and to take advantage of stem cells from reproductive organs to elicit robust anti-cancer immune responses. Here, we showed that vaccination of mice with human amniotic membrane epithelial cells (hAECs) conferred effective protection against colon cancer and led to expansion of systemic and splenic cytotoxic T cell population and induction of cross-protective cytotoxic responses against tumor cells. Vaccinated mice mounted tumor-specific Th1 responses and produced cross-reactive antibodies against cell surface markers of cancer cells. Tumor burden was also significantly reduced in tumor-bearing mice immunized with hAECs. Our findings pave the way for potential future application of hAECs as an effective prophylactic cancer vaccine.
Collapse
Affiliation(s)
- M Tabatabaei
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - N Mosaffa
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - R Ghods
- Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.,Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - S Nikoo
- Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - S Kazemnejad
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
| | - M Khanmohammadi
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
| | - E Mirzadegan
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
| | - A R Mahmoudi
- Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - M R Bolouri
- Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - R Falak
- Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - B Keshavarzi
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M Ramezani
- Department of Biochemistry, School of Medicine, Ardabil University of Medical Science, Ardabil, Iran
| | - A H Zarnani
- Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran.,Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
| |
Collapse
|
3
|
Stinghen ST, Moura JF, Zancanella P, Rodrigues GA, Pianovski MA, Lalli E, Arnold DL, Minozzo JC, Callefe LG, Ribeiro RC, Figueiredo BC. Specific immunoassays for placental alkaline phosphatase as a tumor marker. J Biomed Biotechnol 2010; 2006:56087. [PMID: 17489017 PMCID: PMC1559920 DOI: 10.1155/jbb/2006/56087] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Human placental (hPLAP) and germ cell (PLAP-like) alkaline
phosphatases are polymorphic and heat-stable enzymes. This study
was designed to develop specific immunoassays for quantifying
hPLAP and PLAP-like enzyme activity (EA) in sera of cancer
patients, pregnant women, or smokers. Polyclonal sheep anti-hPLAP
antibodies were purified by affinity chromatography with whole
hPLAP protein (ICA-PLAP assay) or a synthetic peptide (aa 57–71)
of hPLAP (ICA-PEP assay); the working range was 0.1–11 U/L
and cutoff value was 0.2 U/L EA for nonsmokers. The intra-
and interassay coefficients of variation were 3.7%–6.5%
(ICA-PLAP assay) and 9.0%–9.9% (ICA-PEP assay). An
insignificant cross-reactivity was noted for high levels of
unheated intestinal alkaline phosphatase in ICA-PEP assay. A
positive correlation between the regression of tumor size and EA
was noted in a child with embryonal carcinoma. It can be concluded
that ICA-PEP assay is more specific than ICA-PLAP, which is still
useful to detect other PLAP/PLAP-like phenotypes.
Collapse
Affiliation(s)
- Sérvio T. Stinghen
- Centro de Genética Molecular e Pesquisa do
Câncer em Crianças (CEGEMPAC), Rua Agostinho Leão
Júnior, 400 Alto da Glória, Curitiba, PR, CEP 80030-110,
Brazil
| | - Juliana F. Moura
- Centro de Genética Molecular e Pesquisa do
Câncer em Crianças (CEGEMPAC), Rua Agostinho Leão
Júnior, 400 Alto da Glória, Curitiba, PR, CEP 80030-110,
Brazil
| | - Patrícia Zancanella
- Centro de Genética Molecular e Pesquisa do
Câncer em Crianças (CEGEMPAC), Rua Agostinho Leão
Júnior, 400 Alto da Glória, Curitiba, PR, CEP 80030-110,
Brazil
| | - Giovanna A. Rodrigues
- Centro de Genética Molecular e Pesquisa do
Câncer em Crianças (CEGEMPAC), Rua Agostinho Leão
Júnior, 400 Alto da Glória, Curitiba, PR, CEP 80030-110,
Brazil
| | - Mara A. Pianovski
- Division of Pediatric Hematology and Oncology,
Department of Pediatrics, Federal University of Paraná,
Curitiba, PR, CEP 80060-000, Brazil
| | - Enzo Lalli
- Institut de Pharmacologie Moléculaire et
Cellulaire, CNRS UMR 6097, 06560 Valbonne Sophia
Antipolis, France
| | | | - João C. Minozzo
- Center for Research and Production of
Immunoglobulins (CPPI), Rua Targino da Silva s/n, Piraquara, PR, CEP 83302-160, Brazil
| | - Luis G. Callefe
- Centro de Genética Molecular e Pesquisa do
Câncer em Crianças (CEGEMPAC), Rua Agostinho Leão
Júnior, 400 Alto da Glória, Curitiba, PR, CEP 80030-110,
Brazil
| | - Raul C. Ribeiro
- St. Jude Children's Research Hospital, Department of Hematology and Oncology and International Outreach Program,
332 North Lauderdale, Memphis, TN 38105, USA
| | - Bonald C. Figueiredo
- Centro de Genética Molecular e Pesquisa do
Câncer em Crianças (CEGEMPAC), Rua Agostinho Leão
Júnior, 400 Alto da Glória, Curitiba, PR, CEP 80030-110,
Brazil
- Research Institute
Pelé Pequeno Príncipe (IPPP), Avenida Silva Jardim, 1632
Água Verda, Curitiba, PR, CEP 80250-200, Brazil
- *Bonald C. Figueiredo:
| |
Collapse
|
4
|
Brewer BG, Mitchell RA, Harandi A, Eaton JW. Embryonic vaccines against cancer: An early history. Exp Mol Pathol 2009; 86:192-7. [DOI: 10.1016/j.yexmp.2008.12.002] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
5
|
Harandi A. Immunoplacental therapy, a potential multi-epitope cancer vaccine. Med Hypotheses 2006; 66:1182-7. [PMID: 16439066 DOI: 10.1016/j.mehy.2005.12.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2005] [Accepted: 12/01/2005] [Indexed: 12/22/2022]
Abstract
The field of tumor immunology has made great advancements in recent years. A retrospective analysis of previous vaccine strategies combined with present knowledge may provide additional insight in this treatment modality. This article provides a review of immunoplacental therapy (IPT), a cancer vaccine consisting of chorionic villi extractions from the human placenta after a live full-term delivery. This therapy was first introduced in the 1970s by Valentin I. Govallo, M.D., Ph.D., who noted the immunological similarities between pregnancy and cancer. The goal of cancer immunotherapy, according to Govallo, is to view the fetal allograft as an "impregnating tumor" and create an immunological state in the oncological patient analogous to a spontaneous abortion in a pregnant women. The placenta shares identical growth mechanisms, antigenic determinants, and immune-escape properties with cancer cells; this includes numerous tumor-associated antigens, angiogenic growth factors, complement regulatory proteins, and defective apoptotic mechanisms which aid in their survival. Placental vaccination may function as a multi-epitope vaccine; the body recognizes the placental antigens of this vaccine as foreign, and thus stimulates a cross reactive humoral and cell-mediated immune response targeting cancer tumor-associated antigens as well as proteins that aid in cancer angiogenesis, complement regulation, and apoptotic resistance. With recent advancements in molecular and cellular cancer immunology, the model introduced by Govallo may provide an important strategic approach to cancer immunotherapy.
Collapse
Affiliation(s)
- Amir Harandi
- Department of Medicine, St. Luke's-Roosevelt Hospital, Columbia University College of Physicians & Surgeons, New York, NY 10025, USA.
| |
Collapse
|